GlassScriptPhysician profile
Jennifer Biggs
NPI 1265739635
$3,853.72
in general payments reported to CMS, 2019-2025
28 companies · $1,438 in 2025
The $1,438 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $357 · 2022: $303 · 2023: $568 · 2024: $1,188 · 2025: $1,438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,167 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,167.06 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $449.30 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $385.16 | 2024-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $369.75 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $342.48 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Boehringer Ingelheim Pharmaceuticals, INC. | $265.45 | 2021-2023 | Jardiance |
| Alkermes, INC. | $224.24 | 2024-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $219.22 | 2024-2025 | Spravato, Invega Sustenna |
| Astrazeneca Pharmaceuticals LP | $215.74 | 2021-2023 | Farxiga |
| Vanda Pharmaceuticals INC. | $209.82 | 2024-2025 | Fanapt, Hetlioz |
| Novo Nordisk INC | $185.46 | 2021-2023 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $154.98 | 2021-2023 | Trelegy Ellipta |
| Neurocrine Biosciences, INC. | $128.92 | 2024-2025 | Ingrezza |
| Lilly USA, LLC | $104.12 | 2021-2023 | Jardiance, Mounjaro, Emgality |
| Lundbeck LLC | $72.78 | 2024-2025 | Rexulti |
| Abbvie INC. | $70.05 | 2021-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $64.73 | 2023 | |
| Sanofi-Aventis U.S. LLC | $57.49 | 2021-2023 | |
| Corium, LLC | $55.57 | 2024 | Azstarys |
| Noven Therapeutics, LLC | $44.77 | 2024 | Secuado |
| Amgen INC. | $44.36 | 2023 | Otezla, Repatha |
| Axsome Therapeutics, INC. | $42.12 | 2024-2025 | Auvelity |
| Merck Sharp & Dohme LLC | $33.53 | 2023 | Vaxneuvance, Gardasil 9, Rotateq |
| Almatica Pharma LLC | $30.66 | 2024 | Loreev Xr |
| Mylan Specialty L.P. | $22.00 | 2023 | Yupelri |
| Neos Therapeutics, LP | $19.03 | 2024 | Adzenys Xr-Odt |
| Luye Pharma (USA) LTD. | $16.80 | 2025 | Erzofri Extended-Release |
| Sanofi Pasteur INC. | $13.05 | 2023 | |
| Esperion Therapeutics, INC. | $12.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Biggs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.